GlassScriptPhysician profile
James D Salter
NPI 1174628739
$6,399.19
in general payments reported to CMS, 2019-2025
13 companies · $848 in 2025
The $848 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $231 · 2021: $490 · 2022: $1,080 · 2023: $1,289 · 2024: $1,001 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $437 · Entertainment: $300 · Travel and Lodging: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $436.67 |
| Entertainment | $300.00 |
| Travel and Lodging | $199.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,912.37 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $1,067.02 | 2019 | |
| Abb Con-Cise Optical Group LLC | $1,066.85 | 2019-2024 | Contact Lens, Spectacle Lenses |
| Johnson & Johnson Vision Care, INC. | $633.51 | 2020-2025 | Acuvue |
| Alcon Vision LLC | $368.24 | 2019-2025 | Precision 1 |
| Optos, INC. | $150.25 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $49.65 | 2024-2025 | Xdemvy |
| Notal Vision, INC. | $35.00 | 2025 | Foresee Home |
| Dompe US, INC. | $34.96 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $22.41 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $21.01 | 2024 | Zenlens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Salter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.